Market
Which demographic will see the first expanded use of lenacapavir as PrEP by end of 2025?
2
Resolution / Starting Odds
Adolescent girls • 25%
Gender-diverse individuals • 25%
General adult population • 25%
Other • 25%
Clinical trial results and health organization reports
Story
Lenacapavir Named Science's Breakthrough of 2024 for HIV Prevention
Dec 15, 2024, 03:44 PM
The injectable HIV drug lenacapavir has been recognized by the journal 'Science' as the Breakthrough of the Year for 2024. Developed by Gilead Sciences, lenacapavir targets the HIV capsid, a protein shell that protects the virus's genetic material, preventing the virus from replicating within human cells. This drug, administered as a subcutaneous injection every six months, has shown remarkable efficacy in preventing HIV infection, with trials reporting a 100% success rate in African adolescent girls and young women, and a 99.9% effectiveness in gender-diverse individuals. Lenacapavir's unique mechanism of action, as a capsid inhibitor, sets it apart from traditional antiretroviral drugs, offering hope for significantly reducing global HIV infection rates when used as pre-exposure prophylaxis (PrEP).
View original story
Similar markets
Adults • 25%
Adolescents • 25%
Pregnant women • 25%
Elderly • 25%
North America • 25%
Europe • 25%
Asia • 25%
South America • 25%
UK • 25%
USA • 25%
South Africa • 25%
Other • 25%
South Africa • 25%
India • 25%
Other • 25%
United States • 25%
Southeast Asia • 25%
Other • 25%
South America • 25%
Sub-Saharan Africa • 25%
Less than 20% • 25%
More than 60% • 25%
40% to 60% • 25%
20% to 40% • 25%
Africa • 25%
Europe • 25%
North America • 25%
Asia • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%